Extracellular matrix transcriptome dynamics in hepatocellular carcinoma

Matrix Biology

Volumn 32, Issue 7-8, 2013, Pages 393-398

  Duncan, Michael B ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Cancer; Collagen; Glycoprotein; Proteoglycan; RNA Seq

Indexed keywords

AGRIN; COLLAGEN; GLYCOPROTEIN; PERLECAN; PROTEOGLYCAN; SOMATOMEDIN BINDING PROTEIN; THROMBOSPONDIN 1; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR BETA; VERSICAN;

ALTERNATIVE RNA SPLICING; ARTICLE; BINDING SITE; BIOLOGICAL ACTIVITY; CANCER GROWTH; CARCINOGENESIS; CELL ADHESION; DOWN REGULATION; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENETIC VARIABILITY; HUMAN; LIVER CELL CARCINOMA; LIVER REGENERATION; PHENOTYPE; PRIORITY JOURNAL; RNA SEQUENCE; TUMOR MICROENVIRONMENT; UPREGULATION;

CANCER; COLLAGEN; GLYCOPROTEIN; PROTEOGLYCAN; RNA-SEQ;

BASE SEQUENCE; CARCINOMA, HEPATOCELLULAR; COMPUTATIONAL BIOLOGY; EXTRACELLULAR MATRIX PROTEINS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MOLECULAR SEQUENCE DATA; SEQUENCE ANALYSIS, RNA; TRANSCRIPTOME;

EID: 84889090470     PISSN: 0945053X     EISSN: 15691802     Source Type: Journal    
DOI: 10.1016/j.matbio.2013.05.003     Document Type: Article

References (57)

1. Arafat H., Lazar M., Salem K., Chipitsyna G., Gong Q., Pan T.C., Zhang R.Z., Yeo C.J., Chu M.L. Tumor-specific expression and alternative splicing of the COL6A3 gene in pancreatic cancer. Surgery 2011, 150:306-315.
2. Arnold S.A., Rivera L.B., Miller A.F., Carbon J.G., Dineen S.P., Xie Y., Castrillon D.H., Sage E.H., Puolakkainen P., Bradshaw A.D., Brekken R.A. Lack of host SPARC enhances vascular function and tumor spread in an orthotopic murine model of pancreatic carcinoma. Dis. Model. Mech. 2010, 3:57-72.
3. Bedossa P., Paradis V. Liver extracellular matrix in health and disease. J. Pathol. 2003, 200:504-515.
4. Bonnefoy A., Moura R., Hoylaerts M.F. The evolving role of thrombospondin-1 in hemostasis and vascular biology. Cell. Mol. Life Sci. 2008, 65:713-727.
5. Brown D.C., Vogel K.G. Characteristics of the in vitro interaction of a small proteoglycan (PG II) of bovine tendon with type I collagen. Matrix 1989, 9:468-478.
6. Chlenski A., Liu S., Guerrero L.J., Yang Q., Tian Y., Salwen H.R., Zage P., Cohn S.L. SPARC expression is associated with impaired tumor growth, inhibited angiogenesis and changes in the extracellular matrix. Int. J. Cancer 2006, 118:310-316.
7. Coles J.M., Zhang L., Blum J.J., Warman M.L., Jay G.D., Guilak F., Zauscher S. Loss of cartilage structure, stiffness, and frictional properties in mice lacking PRG4. Arthritis Rheum. 2010, 62:1666-1674.
8. Ercolani G., Grazi G.L., Ravaioli M., Del Gaudio M., Gardini A., Cescon M., Varotti G., Cetta F., Cavallari A. Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann. Surg. 2003, 237:536-543.
9. Fang L., Du W.W., Yang X., Chen K., Ghanekar A., Levy G., Yang W., Yee A.J., Lu W.Y., Xuan J.W., Gao Z., Xie F., He C., Deng Z., Yang B.B. Versican 3'-untranslated region (3'-UTR) functions as a ceRNA in inducing the development of hepatocellular carcinoma by regulating miRNA activity. FASEB J. 2012, 27:907-919.
10. Franchini M., Mannucci P.M. Von Willebrand factor: another janus-faced hemostasis protein. Semin. Thromb. Hemost. 2008, 34:663-669.
11. Franchini M., Frattini F., Crestani S., Bonfanti C., Lippi G. von Willebrand factor and cancer: a renewed interest. Thromb. Res. 2013, 131:290-292.
12. Grant D.S., Yenisey C., Rose R.W., Tootell M., Santra M., Iozzo R.V. Decorin suppresses tumor cell-mediated angiogenesis. Oncogene 2002, 21:4765-4777.
13. Gressner A.M., Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J. Cell. Mol. Med. 2006, 10:76-99.
14. Grigioni W.F., D'Errico A., Mancini A.M., Biagini G., Gozzetti G., Mazziotti A., Garbisa S. Hepatocellular carcinoma: expression of basement membrane glycoproteins. An immunohistochemical approach. J. Pathol. 1987, 152:325-332.
15. Han Z.G. Functional genomic studies: insights into the pathogenesis of liver cancer. Annu. Rev. Genomics Hum. Genet. 2012, 13:171-205.
16. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
17. Hayashi H., Sakai K., Baba H., Sakai T. Thrombospondin-1 is a novel negative regulator of liver regeneration after partial hepatectomy through transforming growth factor-beta1 activation in mice. Hepatology 2012, 55:1562-1573.
18. Hedbom E., Heinegard D. Interaction of a 59-kDa connective tissue matrix protein with collagen I and collagen II. J. Biol. Chem. 1989, 264:6898-6905.
19. Hynes R.O. The extracellular matrix: not just pretty fibrils. Science 2009, 326:1216-1219.
20. Hynes R.O. The evolution of metazoan extracellular matrix. J. Cell Biol. 2012, 196:671-679.
21. Hynes R.O., Naba A. Overview of the matrisome - an inventory of extracellular matrix constituents and functions. Cold Spring Harb. Perspect. Biol. 2012, 4:a004903.
22. Ishiyama T., Kano J., Minami Y., Iijima T., Morishita Y., Noguchi M. Expression of HNFs and C/EBP alpha is correlated with immunocytochemical differentiation of cell lines derived from human hepatocellular carcinomas, hepatoblastomas and immortalized hepatocytes. Cancer Sci. 2003, 94:757-763.
23. Jia X.L., Li S.Y., Dang S.S., Cheng Y.A., Zhang X., Wang W.J., Hughes C.E., Caterson B. Increased expression of chondroitin sulphate proteoglycans in rat hepatocellular carcinoma tissues. World J. Gastroenterol. 2012, 18:3962-3976.
24. Kalluri R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat. Rev. Cancer 2003, 3:422-433.
25. Kazerounian S., Yee K.O., Lawler J. Thrombospondins in cancer. Cell. Mol. Life Sci. 2008, 65:700-712.
26. Kelley K.M., Oh Y., Gargosky S.E., Gucev Z., Matsumoto T., Hwa V., Ng L., Simpson D.M., Rosenfeld R.G. Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. Int. J. Biochem. Cell Biol. 1996, 28:619-637.
27. Kim S., Takahashi H., Lin W.W., Descargues P., Grivennikov S., Kim Y., Luo J.L., Karin M. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 2009, 457:102-106.
28. Kuemmerle J.F. Insulin-like growth factors in the gastrointestinal tract and liver. Endocrinol. Metab. Clin. North Am. 2012, 41:409-423. (vii).
29. Li B., Dewey C.N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinforma. 2011, 12:323.
30. Lopez-Dee Z., Pidcock K., Gutierrez L.S. Thrombospondin-1: multiple paths to inflammation. Mediators Inflamm. 2011, 2011:296069.
31. Lu P., Weaver V.M., Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J. Cell Biol. 2012, 196:395-406.
32. Mardis E.R., Wilson R.K. Cancer genome sequencing: a review. Hum. Mol. Genet. 2009, 18:R163-R168.
33. Mongiat M., Sweeney S.M., San Antonio J.D., Fu J., Iozzo R.V. Endorepellin, a novel inhibitor of angiogenesis derived from the C terminus of perlecan. J. Biol. Chem. 2003, 278:4238-4249.
34. Motosugi U., Ichikawa T., Koshiishi T., Sano K., Morisaka H., Ichikawa S., Enomoto N., Matsuda M., Fujii H., Araki T. Liver stiffness measured by magnetic resonance elastography as a risk factor for hepatocellular carcinoma: a preliminary case-control study. Eur. Radiol. 2013, 23:156-162.
35. Naba A., Clauser K.R., Hoersch S., Liu H., Carr S.A., Hynes R.O. The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices. Mol. Cell. Proteomics 2012, 11. (M111 014647).
36. Neill T., Schaefer L., Iozzo R.V. Decorin: a guardian from the matrix. Am. J. Pathol. 2012, 181:380-387.
37. Ricciardelli C., Sakko A.J., Ween M.P., Russell D.L., Horsfall D.J. The biological role and regulation of versican levels in cancer. Cancer Metastasis Rev. 2009, 28:233-245.
38. Said N., Sanchez-Carbayo M., Smith S.C., Theodorescu D. RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration. J. Clin. Invest. 2012, 122:1503-1518.
39. Said N., Frierson H.F., Sanchez-Carbayo M., Brekken R.A., Theodorescu D. Loss of SPARC in bladder cancer enhances carcinogenesis and progression. J. Clin. Invest. 2013, 123:751-766.
40. Seitz H.K., Stickel F. Risk factors and mechanisms of hepatocarcinogenesis with special emphasis on alcohol and oxidative stress. Biol. Chem. 2006, 387:349-360.
41. Shendure J., Ji H. Next-generation DNA sequencing. Nat. Biotechnol. 2008, 26:1135-1145.
42. Sheng W., Wang G., Wang Y., Liang J., Wen J., Zheng P.S., Wu Y., Lee V., Slingerland J., Dumont D., Yang B.B. The roles of versican V1 and V2 isoforms in cell proliferation and apoptosis. Mol. Biol. Cell 2005, 16:1330-1340.
43. Sherman-Baust C.A., Weeraratna A.T., Rangel L.B., Pizer E.S., Cho K.R., Schwartz D.R., Shock T., Morin P.J. Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell 2003, 3:377-386.
44. Svensson L., Heinegard D., Oldberg A. Decorin-binding sites for collagen type I are mainly located in leucine-rich repeats 4-5. J. Biol. Chem. 1995, 270:20712-20716.
45. Tatrai P., Dudas J., Batmunkh E., Mathe M., Zalatnai A., Schaff Z., Ramadori G., Kovalszky I. Agrin, a novel basement membrane component in human and rat liver, accumulates in cirrhosis and hepatocellular carcinoma. Lab. Invest. 2006, 86:1149-1160.
46. Wagner D.D. Cell biology of von Willebrand factor. Annu. Rev. Cell Biol. 1990, 6:217-246.
47. Wang Z., Gerstein M., Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat. Rev. Genet. 2009, 10:57-63.
48. Wenstrup R.J., Florer J.B., Brunskill E.W., Bell S.M., Chervoneva I., Birk D.E. Type V collagen controls the initiation of collagen fibril assembly. J. Biol. Chem. 2004, 279:53331-53337.
49. Wenstrup R.J., Florer J.B., Cole W.G., Willing M.C., Birk D.E. Reduced type I collagen utilization: a pathogenic mechanism in COL5A1 haplo-insufficient Ehlers-Danlos syndrome. J. Cell. Biochem. 2004, 92:113-124.
50. Whitelock J.M., Melrose J., Iozzo R.V. Diverse cell signaling events modulated by perlecan. Biochemistry 2008, 47:11174-11183.
51. Wu J., Zhu A.X. Targeting insulin-like growth factor axis in hepatocellular carcinoma. J. Hematol. Oncol. 2011, 4:30.
52. Xiong Y.Q., Sun H.C., Zhang W., Zhu X.D., Zhuang P.Y., Zhang J.B., Wang L., Wu W.Z., Qin L.X., Tang Z.Y. Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells. Clin. Cancer Res. 2009, 15:4838-4846.
53. Yang W., Yee A.J. Versican V2 isoform enhances angiogenesis by regulating endothelial cell activities and fibronectin expression. FEBS Lett. 2013, 587:185-192.
54. Yurchenco P.D. Basement membranes: cell scaffoldings and signaling platforms. Cold Spring Harb. Perspect. Biol. 2011, 3.
55. Zeisberg M., Kramer K., Sindhi N., Sarkar P., Upton M., Kalluri R. De-differentiation of primary human hepatocytes depends on the composition of specialized liver basement membrane. Mol. Cell. Biochem. 2006, 283:181-189.
56. Zhang D.Y., Friedman S.L. Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology 2012, 56:769-775.
57. Zhao G., Cui J., Qin Q., Zhang J., Liu L., Deng S., Wu C., Yang M., Li S., Wang C. Mechanical stiffness of liver tissues in relation to integrin beta1 expression may influence the development of hepatic cirrhosis and hepatocellular carcinoma. J. Surg. Oncol. 2010, 102:482-489.